Relacorilant is being evaluated in two Phase 3 clinical trials, with data expected in 2024. The therapy’s developer, Corcept Therapeutics, has indicated plans to seek regulatory approval after those data become available; however, it is not known if or when relacorilant will be approved.
Relacorilant is an investigational therapy that works to block the receptor proteins through which the hormone cortisol exerts its effects. In doing so, it is expected to ease the symptoms — such as elevated blood sugar levels and high blood pressure — that arise due to excess cortisol in Cushing’s disease and other forms of Cushing’s syndrome.
There are no data indicating an interaction between relacorilant, a treatment candidate for endogenous Cushing’s syndrome, and alcohol. However, the therapy is still being tested in clinical trials and it is not yet established whether patients on relacorilant will be able to safely to drink alcohol. Patients should speak with their doctor if they are planning to drink while being on this therapy.
In a Phase 2 trial involving Cushing’s patients, reductions in blood sugar and blood pressure were evident in some participants at three months following the start of treatment. However, it’s not yet clear how soon a significant effect of treatment on blood pressure and blood sugar levels may be seen in Cushing’s patients. Additional data will be needed to better understand when any effects may become evident.
The most common side effects reported in clinical trials of relacorilant to date include back pain, swelling, headache, nausea, pain in the extremities, diarrhea, and dizziness. However, patients may experience other side effects while on the therapy, so it’s important they ask their doctor how the medication may affect them.